±¸Á¶½ÉÁúȯ¿¬±¸È¸ The 4th K-SCI(Korea-Structural Cardiovascular Intervention) Symposium : 2021-11-20±³À°ÀÏÀÚ : 2021-11-20
±³À°Àå¼Ò : ¼¿ï ÄÚ¿¢½º ÄÁÆÛ·±½º·ë(³²) ±×·£µåÄÁÆÛ·±½º·ë 401È£(4F)
±³À°ÁÖÁ¦ :
The 4th K-SCI(Korea-Structural Cardiovascular Intervention) SymposiumÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ±¸Á¶½ÉÁúȯ¿¬±¸È¸
´ã´çÀÚ : Á¤ÀºÇý
¿¬¶ôó : 02-582-8212
À̸ÞÀÏ :
grace@kscvi.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-20 401È£ 09:10~09:20 ASD Closure in Adults with Diastolic Dysfunction and/or Pulmonary Hypertension ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 09:20~09:30 Transcatheter Closure of ASD with Complex Anatomy (Multiple Holes, Rim Deficiency) Çϱâ¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 09:30~09:40 PFO Closure with Difficulty Anatomy; Long Tunnel, Multiple Holes ÃÖÀ翵(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 09:40~09:50 PFO Closure in the Elderly ÀÌÇÊÇü(¿ï»êÀÇ´ë)
Åä·Ð 11-20 401È£ 09:50~10:10 Discussion ()
ÈÞ½Ä 11-20 10:10~10:20 Break ()
±³À°½Ã°£ 11-20 401È£ 10:20~10:35 TAVR in Patients with Difficult Transfemoral Access ±èÁÖÇÑ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 10:35~10:50 TAVR in Patients with Type 0 Bicuspid AV with Heavy Calcification ¹ÚÅñÔ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 10:50~11:05 TAVR in Patients with Low Coronary Ostium and Small SOV À¯Ã¶¿õ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 11:05~11:20 ViV TMVR Case Â÷Á¤ÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 11:20~11:35 TAVR in Patients with Very Tortuous Aorta ÀÌöÇö(°è¸íÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 11:35~11:50 TAVR in Patients with Decompensated HF with Low EF ¼Áö¿ø(¿¬¼¼ÀÇ´ë)
Åä·Ð 11-20 401È£ 11:50~12:00 Discussion ()
ÈÞ½Ä 11-20 12:00~13:00 Lunch Break ()
±³À°½Ã°£ 11-20 401È£ 13:00~13:10 Guidelines Update: How to Apply in Daily Practice? °¿õö(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 13:10~13:20 Update on TAVR Clinical Trials °ÁöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 13:20~13:30 Optimal Antithrombotic Therapy after TAVR Á¶Àͼº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 13:30~13:40 Updated Clinical Evidence on Embolic Protection Device Àå±âÀ°(°¡Å縯ÀÇ´ë)
Åä·Ð 11-20 401È£ 13:40~14:00 Discussion ()
ÈÞ½Ä 11-20 14:00~14:10 Break ()
±³À°½Ã°£ 11-20 401È£ 14:10~14:20 Secondary MR in HFrEF, How to Select the Best Candidates for Mitraclip? ±èÁß¼±(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 14:20~14:30 Secondary MR after AMI, What Is the Optimal Timing for Mitraclip? È«¼ºÁø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 14:30~14:40 Mixed Primary and Secondary MR, How to Treat? °µµÀ±(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 14:40~14:50 Mitraclip for Primary MR with Unfavorable Anatomy, How to Overcome? Ȳº´Èñ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 14:50~15:00 MR with Bioprosthetic Valve Failure, How to Treat? ±¹Çüµ·(ÇѾçÀÇ´ë)
±³À°½Ã°£ 11-20 401È£ 15:00~15:10 Device Closure of Paravalvular Leakage after Mechanical MVR ¾ÈÁ¤¹Î(¿ï»êÀÇ´ë)
Åä·Ð 11-20 401È£ 15:10~15:30 Discussion ()